Innophos Holdings, Inc. (NASDAQ:IPHS) has been assigned a consensus broker rating score of 2.00 (Buy) from the two analysts that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation and one has assigned a strong buy recommendation to the company. Innophos’ rating score has improved by 33.3% in the last 90 days as a result of a number of analysts’ ratings changes.
Brokerages have set a 1-year consensus price target of $51.00 for the company and are predicting that the company will post $0.43 EPS for the current quarter, according to Zacks. Zacks has also assigned Innophos an industry rank of 190 out of 255 based on the ratings given to related companies.
Several research analysts recently weighed in on IPHS shares. TheStreet upgraded Innophos from a “c” rating to a “b-” rating in a research report on Thursday, February 21st. BidaskClub cut Innophos from a “buy” rating to a “hold” rating in a research report on Friday, March 1st. Zacks Investment Research upgraded Innophos from a “strong sell” rating to a “hold” rating in a research report on Friday, January 4th. ValuEngine upgraded Innophos from a “strong sell” rating to a “sell” rating in a research report on Monday, February 4th. Finally, Seaport Global Securities started coverage on Innophos in a research report on Thursday, February 21st. They set a “buy” rating for the company.
A number of institutional investors and hedge funds have recently modified their holdings of IPHS. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in Innophos in the third quarter valued at approximately $208,000. Bank of New York Mellon Corp grew its holdings in Innophos by 3.8% in the third quarter. Bank of New York Mellon Corp now owns 402,003 shares of the specialty chemicals company’s stock valued at $17,849,000 after purchasing an additional 14,662 shares during the period. BlackRock Inc. grew its holdings in Innophos by 5.1% in the third quarter. BlackRock Inc. now owns 2,800,584 shares of the specialty chemicals company’s stock valued at $124,346,000 after purchasing an additional 134,916 shares during the period. Dimensional Fund Advisors LP grew its holdings in Innophos by 0.9% in the third quarter. Dimensional Fund Advisors LP now owns 1,045,918 shares of the specialty chemicals company’s stock valued at $46,438,000 after purchasing an additional 9,652 shares during the period. Finally, MetLife Investment Advisors LLC grew its holdings in Innophos by 54.2% in the third quarter. MetLife Investment Advisors LLC now owns 14,198 shares of the specialty chemicals company’s stock valued at $630,000 after purchasing an additional 4,991 shares during the period. 93.45% of the stock is currently owned by institutional investors.
IPHS stock traded down $0.46 during trading on Wednesday, hitting $32.15. 53,700 shares of the company traded hands, compared to its average volume of 117,008. The company has a current ratio of 2.52, a quick ratio of 1.13 and a debt-to-equity ratio of 0.89. The stock has a market cap of $636.15 million, a P/E ratio of 14.10 and a beta of 1.31. Innophos has a 1 year low of $22.57 and a 1 year high of $50.40.
Innophos (NASDAQ:IPHS) last announced its quarterly earnings results on Wednesday, February 20th. The specialty chemicals company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.51 by $0.03. The company had revenue of $192.74 million during the quarter, compared to analysts’ expectations of $189.60 million. Innophos had a return on equity of 13.39% and a net margin of 4.50%. Innophos’s quarterly revenue was down .2% on a year-over-year basis. During the same period last year, the business earned $0.52 earnings per share. On average, research analysts predict that Innophos will post 2.23 earnings per share for the current fiscal year.
Innophos Holdings, Inc, together with its subsidiaries, produces specialty ingredients with applications in food, health, nutrition, and industrial markets. It operates through three segments: Food, Health and Nutrition; Industrial Specialties; and Other. The company's specialty ingredients include specialty phosphate salts and specialty phosphoric acids, as well as other mineral, enzyme, and botanical based specialty ingredients that are used as flavor enhancers in beverages; electrolytes in sports drinks; texture modifiers in cheeses; leavening agents in baked goods; calcium and phosphorus fortification in food and beverages; moisture and color retention in seafood, poultry, and meat; excipients in vitamins, minerals, nutritional supplements, and pharmaceuticals; and abrasives in toothpaste.
See Also: What is a capital gain?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Innophos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innophos and related companies with MarketBeat.com's FREE daily email newsletter.